TY - JOUR
T1 - Suppression of phagocytic cells in retinal disorders using amphiphilic poly(γ-glutamic acid) nanoparticles containing dexamethasone
AU - Ryu, Morin
AU - Nakazawa, Toru
AU - Akagi, Takami
AU - Tanaka, Tatsuhide
AU - Watanabe, Ryou
AU - Yasuda, Masayuki
AU - Himori, Noriko
AU - Maruyama, Kazuichi
AU - Yamashita, Toshihide
AU - Abe, Toshiaki
AU - Akashi, Mitsuru
AU - Nishida, Kohji
N1 - Funding Information:
We thank Prof. Larry. I. Benowitz (Children's Hospital, Harvard Medical School) for editing this manuscript and Mr. Jiro Watanabe and Koutaro Yamamoto for technical assistance. This study was supported by Grants-in-Aid from the Ministry of Education, Science and Technology of Japan ( 21659395 and 22689045 , T.N.), the Uehara Memorial Research Foundation , the Takeda Research Foundation , the Imai Glaucoma Research Foundation (T.N.), and CREST from the Japan Science and Technology Agency (T. A. and M. A.).
PY - 2011/4/10
Y1 - 2011/4/10
N2 - To investigate the potential of nanoparticles (NPs) composed of poly(γ-glutamic acid) conjugated with l-phenylalanine (γ-PGA-Phe NPs) for the treatment of retinal diseases,γ-PGA-Phe NPs (200 nm) were tested with macrophages and microglia in vitro or by intravitreal administration into normal or pathological rat eyes. The anti-inflammatory effects of the NPs containing dexamethasone (DEX-NPs) were examined using qRT-PCR in vitro by counting activated microglia and Fluorogold-labeled retinal ganglion cells in the retinas under excitotoxicity or by counting TUNEL (+) photoreceptors in the detached retinas. The NPs were taken up efficiently by cultured macrophages or microglia. At day 7, 60-80% of the diffuse signal remained in the cytoplasm of these cells. In normal rat eyes, the NPs did not accumulate in the retinas and no inflammatory cells were recruited. Conversely, under pathological conditions, the NPs were localized in activated CD11b-positive cells in the retina. DEX-NPs suppressed the expression of TNFα and MCP-1 in cultured macrophages or microglia, the activation of microglia, the loss of retinal ganglion cells (RGCs) in excitotoxic retinas, and the number of TUNEL (+) photoreceptors in detached retinas. These data suggest that γ-PGA-Phe NPs can be a powerful tool for suppressing inflammatory cells in pathological conditions in the retina.
AB - To investigate the potential of nanoparticles (NPs) composed of poly(γ-glutamic acid) conjugated with l-phenylalanine (γ-PGA-Phe NPs) for the treatment of retinal diseases,γ-PGA-Phe NPs (200 nm) were tested with macrophages and microglia in vitro or by intravitreal administration into normal or pathological rat eyes. The anti-inflammatory effects of the NPs containing dexamethasone (DEX-NPs) were examined using qRT-PCR in vitro by counting activated microglia and Fluorogold-labeled retinal ganglion cells in the retinas under excitotoxicity or by counting TUNEL (+) photoreceptors in the detached retinas. The NPs were taken up efficiently by cultured macrophages or microglia. At day 7, 60-80% of the diffuse signal remained in the cytoplasm of these cells. In normal rat eyes, the NPs did not accumulate in the retinas and no inflammatory cells were recruited. Conversely, under pathological conditions, the NPs were localized in activated CD11b-positive cells in the retina. DEX-NPs suppressed the expression of TNFα and MCP-1 in cultured macrophages or microglia, the activation of microglia, the loss of retinal ganglion cells (RGCs) in excitotoxic retinas, and the number of TUNEL (+) photoreceptors in detached retinas. These data suggest that γ-PGA-Phe NPs can be a powerful tool for suppressing inflammatory cells in pathological conditions in the retina.
KW - Cytokines
KW - Drug delivery
KW - Microglia
KW - Monocyte recruitment
KW - Nanoparticles
KW - Neuroprotection
UR - http://www.scopus.com/inward/record.url?scp=79955471838&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79955471838&partnerID=8YFLogxK
U2 - 10.1016/j.jconrel.2010.11.029
DO - 10.1016/j.jconrel.2010.11.029
M3 - Article
C2 - 21130816
AN - SCOPUS:79955471838
SN - 0168-3659
VL - 151
SP - 65
EP - 73
JO - Journal of Controlled Release
JF - Journal of Controlled Release
IS - 1
ER -